A survey conducted by the National Comprehensive Cancer Network found that 93% of its 27 member institutions are experiencing shortages of carboplatin, and 70% lack cisplatin.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe